Background Recent registries have shown that recommended drugs for the treatment of
chronic heart failure (CHF) are under‐prescribed in daily practice. Aims To determine …

Aims Recent studies have shown that prescription rates and doses of recommended drugs
for chronic heart failure (CHF) are not optimal in daily practice. The aim of the Impact‐Reco …

Aims To evaluate how recommendations of European guidelines regarding
pharmacological and non‐pharmacological treatments for heart failure (HF) are adopted in …

Background Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor
blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists (MRAs) are of …

Chronic heart failure (CHF) is associated with a high burden of mortality and morbidity and is
the leading principal hospital diagnosis among older adults. As a result of the complexities …

Background Heart failure (HF) is a global health problem. Guidelines for the management of
HF have been established in Western countries and in Taiwan. However, data from the …

Aims Surveys on heart failure management suggest under-utilization of life-saving evidence-
based treatment. Evidence-based medicine and clinical guidelines are based on the results …

Background: Heart failure has a poor prognosis, yet drugs known to improve outcomes are
either not prescribed, or prescribed at sub‐therapeutic doses. The National Service …

Aims Patients with heart failure (HF) randomized in controlled trials are generally selected
and do not fully represent the 'real world'. The purpose of this study is to better describe the …

The extent and impact of under-prescribing of evidence-based pharmacological therapies
among heart failure patients with reduced ejection fraction (HFREF) in contemporary …